MDXH: Record sequential revenue growth and strong outlook as core urology business drives recovery
MDxHealth SA (MDXH) reported Q2 2026 revenue up 16% year over year and its largest sequential growth, citing a renewed focus on core urology diagnostics after discontinuing the Resolve UTI business. The company reaffirmed 2026 revenue guidance of $110–$115 million and a return to adjusted EBITDA profitability.
How this was made
The 30-second read
Why it matters
Guidance reaffirmation for 2026 revenue ($110–$115M) and a return to adjusted EBITDA profitability can shift expectations for forward earnings power and risk premium.
Market read
Traders can reassess MDxHealth’s forward revenue and profitability trajectory based on the reaffirmed 2026 outlook and the business-line reset.
What to watch
The summary does not quantify adjusted EBITDA margin, cash burn, or whether the core urology diagnostics growth offsets any lost revenue from Resolve UTI beyond the stated guidance.
Background
The company attributes the recovery to renewed focus on core urology diagnostics after discontinuing the Resolve UTI business.
Ticker impact
MDxHealth reports Q2 2026 revenue up 16% YoY, largest sequential growth, and reaffirms 2026 revenue guidance of $110–$115M.
Near-term upside bias as guidance and profitability trajectory improve, though magnitude depends on how the market priced the prior Resolve UTI discontinuation.
The article provides concrete quarterly growth, a specific 2026 revenue range, and a profitability return, which are actionable for valuation and positioning.
Market effects
Signals potential stabilization in urology diagnostics demand and improved execution after discontinuing a product line.
No specific regional impact stated.
Limited to company-specific guidance and business-line shift.
Counterpoint
Revenue growth and guidance reaffirmation may still be insufficient if investors focus on durability of margins or competitive intensity in UTI diagnostics.
Key entities
- companyMDxHealth SA
Reports Q2 2026 revenue growth, largest sequential growth in company history, and reaffirms 2026 revenue guidance and profitability return.
